CN111067919A - 喷雾止痛剂 - Google Patents
喷雾止痛剂 Download PDFInfo
- Publication number
- CN111067919A CN111067919A CN201911333570.1A CN201911333570A CN111067919A CN 111067919 A CN111067919 A CN 111067919A CN 201911333570 A CN201911333570 A CN 201911333570A CN 111067919 A CN111067919 A CN 111067919A
- Authority
- CN
- China
- Prior art keywords
- parts
- analgesic
- chitosan
- spray
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 25
- 239000007921 spray Substances 0.000 title claims abstract description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 210000003608 fece Anatomy 0.000 claims abstract description 19
- 241000301400 Trogopterus Species 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 17
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims abstract description 15
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims abstract description 15
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims abstract description 13
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims abstract description 13
- 208000002193 Pain Diseases 0.000 abstract description 13
- 208000000094 Chronic Pain Diseases 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 4
- 229960004194 lidocaine Drugs 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 13
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 239000000730 antalgic agent Substances 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZQBMUHABRSEAIK-UXBLZVDNSA-N 1-[4-[(e)-3-phenylprop-2-enyl]piperazin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCN1C\C=C\C1=CC=CC=C1 ZQBMUHABRSEAIK-UXBLZVDNSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- -1 amcinolone Chemical compound 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 229960000751 nefopam Drugs 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930189907 rotundine Natural products 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
本发明提供一种新型的喷雾止痛剂，由二甲亚砜、水溶性氮酮、利多卡因、地塞米松磷酸钠、五灵脂与壳聚糖组成，以体积配比为：二甲亚砜55~65份、水溶性氮酮2~4份、盐酸利多卡因20~30份、地塞米松磷酸钠含量为5份、五灵脂4份、壳聚糖2份。具有用于针对长期慢性疼痛的问题，以及解决现有止痛药长期使用会对身体造成损害的问题。
Description
技术领域
本发明涉及医药技术领域，具体而言涉及一种喷雾止痛剂。
背景技术
镇痛药，可防治疼痛引起的严重生理紊乱，在临床治疗中具有重要意义。一般可分为二大类，即阿片类镇痛药（又称麻醉性镇痛药）和非麻醉性镇痛药。
麻醉性镇痛药常用的有：派替啶、芬太尼、可待因、吗啡、杜冷丁、布桂嗪（强痛定）、阿片、氨酚羟考酮、纳洛酮、四氢帕马丁、罗通定、曲马多、奈福泮、苯噻啶等。目前使用的强效阿片类药用后可能有“成瘾性”等不良反应。因此受严格控制，一般只限于中到重度急性短暂应用或和癌症的末期应用。
另一类是非麻醉性镇痛药，最常用的有解热镇痛抗炎药（即非甾体抗炎药，NSAIDs）是一类具有解热、镇痛作用，大部分还兼有抗炎和抗风湿作用的药物。按化学结构可分为：①水杨酸类（甲酸类），如阿司匹林；②乙酸类：如吲哚美辛；③丙酸类：如布洛芬；④昔康类：如吡罗昔康；⑤昔布类：如塞来昔布；⑥吡唑酮类，如保泰松；⑦其他类：如尼美舒利等等。它们的共同特点是止痛效果确实，但对身体内脏的损害也很大，尤其对消化系统的损害最明显，所以难以长期常规应用。
此外，临床还有抗风湿止痛，抗痛风止痛等药物，也因其对人体内脏副作用太大，无法长期应用。
还有一种是局部麻醉止痛，是一种能暂时完全和可逆地阻滞神经传导功能的药物，代表药物如利多卡因。给药途径多为封闭注射。对长期慢性疼痛的用药也不方便和不合适。
发明内容
本发明的目的在于针对现有止痛药的缺点，开发出一种新型的喷雾止痛剂，用于针对长期慢性疼痛的问题，解决现有止痛药长期使用会对身体造成损害的问题。
为了实现上述目的，本发明提供的一种喷雾止痛剂，由二甲亚砜、水溶性氮酮、利多卡因、地塞米松磷酸钠、五灵脂与壳聚糖组成。
优选的，以体积配比为：二甲亚砜55~65份、水溶性氮酮2~4份、盐酸利多卡因20~30份、地塞米松磷酸钠含量为5份、五灵脂4份、壳聚糖2份。
优选的，以体积配比为：二甲亚砜60份、水溶性氮酮4份、盐酸利多卡因25份、地塞米松磷酸钠5份、五灵脂4份、壳聚糖2份。
优选的，所述壳聚糖为浓度12%的壳聚糖溶液。
优选的，所述盐酸利多卡因是浓度2%的盐酸利多卡因溶液。
优选的，所述五灵脂为五灵脂熬出的浓缩液。
本发明的优点在于：
药物配制机理：二甲亚砜是目前最著名而常用的药物透皮促进剂，它可与水形成氢键，具有脂溶性与水溶性，极强的穿透性，溶解与运载药物能力的特点而又不与药物产生化学反应，是惰性液体，表皮在它的作用下，细胞膜中的蛋白质发生可逆性构形变化，可以置换角质中的“结合水”，并形成一种疏松的结构而增强其穿透能力。它在相对湿度为65%、20℃时，可吸收其重量70%的水，使皮肤中的水含量增加，也是能增加药物渗透性的机制之一。二甲亚砜的这些特征，使我们能准确估算治疗药物的作用剂量和靶组织的位置。可以起到如局部封闭一样的效果而又避免“注射”。
水溶性氮酮的透皮作用更强，本发明将二甲亚砜、水溶性氮酮与利多卡因共同外用，效果确可比肩“局部封闭”。
至于配制份量比例问题，透皮剂的比例太高会影响治疗药物的比例而减弱治疗效果。比例太低又会影响治疗药物起效时间。经无数次实验，拟以本发明上述比例较为理想。
药物作用机理：
盐酸利多卡因，化学名：N-（2,6二甲苯基）-2-（二乙氨基）乙酰铵盐酸盐-水合物。临床常用于浸润麻醉作局麻药应用，止痛效果绝对胜任手术创伤。
地塞米松磷酸钠，临床用于抗过敏和缓解应激有重要作用。
五灵脂是鼯鼠的干燥粪尿，性味咸、甘、温，有活血化瘀、止痛等功能。临床用于治疗妇女的月经不调、瘀血腹痛等。另外，也有治疗肿痛、跌打损伤、蛇、蝎、蜈蚣、蜂、毒虫咬伤等症。
壳聚糖与五灵脂的共同使用，可以有效提高血液ph值以及促进细胞内堆积的酸性代谢产物分解，改善血液循环。
本发明在甲亚砜、水溶性氮酮、盐酸利多卡因、地塞米松磷酸钠、五灵脂与壳聚糖的共同作用下，喷在疼痛位置，可以有效解决长期慢性疼痛问题。快速解除疼痛，然后解除痛部肌肉痉挛，改善血液循环，促进代谢产物排放，形成中医所述的“通则不痛”，建立良性循环，病情更快好转，达到标本兼治。
具体实施方式
下面对本发明作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案，而不能以此来限制本发明的保护范围。
实施例1：一种喷雾止痛剂，以体积配比为：二甲亚砜55份、水溶性氮酮4份、盐酸利多卡因30份、地塞米松磷酸钠含量为5份、五灵脂4份、壳聚糖2份。
实施例2：一种喷雾止痛剂，以体积配比为：二甲亚砜65份、水溶性氮酮2份、盐酸利多卡因20份、地塞米松磷酸钠含量为5份、五灵脂4份、壳聚糖2份。
实施例3：一种喷雾止痛剂，以体积配比为：二甲亚砜60份、水溶性氮酮4份、盐酸利多卡因25份、地塞米松磷酸钠5份、五灵脂4份、壳聚糖2份。
实施例4：
为了验证实施例1~3的解决长期慢性疼痛效果，本发明申请人找来了90名多年受风湿、痛风影响的自愿者参与使用本产品，并对于治疗效果进行反馈。
反馈方法：自愿者疼痛次数、时间开始减少的情况进行登记。
判断方法：使用者以与未使用本产品前做对比，以依赖止痛剂、止痛药的次数减少
为具有治疗效果，以完全无需再依赖止痛剂、止痛药为具有显著治疗效果。实验结果如下表
1。
| 有效人数 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 | 有效比例 |
| 具有治疗效果人数 | 1 | 8 | 25 | 46 | 75 | 88 | 88 | 88 | 88 | 88 | 88 | 88 | 97% |
| 具有显著治疗效果人数 | 0 | 0 | 0 | 2 | 9 | 14 | 36 | 67 | 71 | 72 | 72 | 72 | 80% |
试验结构表明，本发明对具有长期慢性疼痛患者在使用本发明产品后1年内治疗效果有效比例为97%，具有效率高，针对性强的特点，而且大部分患者在使用本产品6个月内就能感受到明显的有效改善，治疗时间短。
最后应说明的是：显然，上述实施例仅仅是为清楚地说明本发明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引申出的显而易见的变化或变动仍处于本发明的保护范围之中。
Claims (6)
1.喷雾止痛剂，其特征在于，由二甲亚砜、水溶性氮酮、盐酸利多卡因、地塞米松磷酸钠、五灵脂与壳聚糖组成。
2.根据权利要求1所述的喷雾止痛剂，其特征在于，以体积配比为：二甲亚砜55~65份、水溶性氮酮2~4份、盐酸利多卡因20~30份、地塞米松磷酸钠含量为5份、五灵脂4份、壳聚糖2份。
3.根据权利要求2所述的喷雾止痛剂，其特征在于，以体积配比为：二甲亚砜60份、水溶性氮酮4份、盐酸利多卡因25份、地塞米松磷酸钠5份、五灵脂4份、壳聚糖2份。
4.根据权利要求1所述的喷雾止痛剂，其特征在于，所述壳聚糖为浓度12%的壳聚糖溶液。
5.根据权利要求1所述的喷雾止痛剂，其特征在于，所述盐酸利多卡因是浓度2%的盐酸利多卡因溶液。
6.根据权利要求1所述的喷雾止痛剂，其特征在于，所述五灵脂为五灵脂熬出的浓缩液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911333570.1A CN111067919A (zh) | 2019-12-23 | 2019-12-23 | 喷雾止痛剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911333570.1A CN111067919A (zh) | 2019-12-23 | 2019-12-23 | 喷雾止痛剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111067919A true CN111067919A (zh) | 2020-04-28 |
Family
ID=70316638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911333570.1A Pending CN111067919A (zh) | 2019-12-23 | 2019-12-23 | 喷雾止痛剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111067919A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113768876A (zh) * | 2021-09-02 | 2021-12-10 | 曹福林 | 一种用于止痛喷雾消淤制剂及制作方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030054017A1 (en) * | 2001-09-17 | 2003-03-20 | Castillo James G. | Alcohol based topical anesthetic formulation and method |
| WO2007070694A2 (en) * | 2005-12-14 | 2007-06-21 | Zars, Inc. | Spray-on formulations and methods for dermal delivery of drugs |
| CA2747845A1 (en) * | 2005-12-14 | 2007-06-21 | Zars Pharma, Inc. | Compositions and methods for dermally treating pain |
| CN101357116A (zh) * | 2007-08-03 | 2009-02-04 | 谭国梁 | 透皮透粘膜局部麻醉止痛剂及其凝胶性制剂的制备方法 |
| CN103505791A (zh) * | 2012-06-28 | 2014-01-15 | 杨德普 | 透皮吸收局麻无痛注射穿刺酒精棉片 |
| CN110075169A (zh) * | 2019-06-10 | 2019-08-02 | 西南医科大学附属医院 | 一种用于治疗慢性疼痛的复合透皮贴片及其制备方法 |
| CN110478334A (zh) * | 2019-06-24 | 2019-11-22 | 武汉兵兵药业有限公司 | 一种用于肌肉、关节止痛镇痛水凝胶贴膏剂及其制备方法 |
-
2019
- 2019-12-23 CN CN201911333570.1A patent/CN111067919A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030054017A1 (en) * | 2001-09-17 | 2003-03-20 | Castillo James G. | Alcohol based topical anesthetic formulation and method |
| WO2007070694A2 (en) * | 2005-12-14 | 2007-06-21 | Zars, Inc. | Spray-on formulations and methods for dermal delivery of drugs |
| CA2747845A1 (en) * | 2005-12-14 | 2007-06-21 | Zars Pharma, Inc. | Compositions and methods for dermally treating pain |
| CN101357116A (zh) * | 2007-08-03 | 2009-02-04 | 谭国梁 | 透皮透粘膜局部麻醉止痛剂及其凝胶性制剂的制备方法 |
| CN103505791A (zh) * | 2012-06-28 | 2014-01-15 | 杨德普 | 透皮吸收局麻无痛注射穿刺酒精棉片 |
| CN110075169A (zh) * | 2019-06-10 | 2019-08-02 | 西南医科大学附属医院 | 一种用于治疗慢性疼痛的复合透皮贴片及其制备方法 |
| CN110478334A (zh) * | 2019-06-24 | 2019-11-22 | 武汉兵兵药业有限公司 | 一种用于肌肉、关节止痛镇痛水凝胶贴膏剂及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 胡晋红主编: "《实用医院药学 第2版》", 30 November 2007 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113768876A (zh) * | 2021-09-02 | 2021-12-10 | 曹福林 | 一种用于止痛喷雾消淤制剂及制作方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220142953A1 (en) | Lidocaine patch and methods of use thereof | |
| JPH0780761B2 (ja) | 痛みのある疾患又はアレルギー性疾患の治療用組成物及び治療法 | |
| WO2015024420A1 (zh) | 局麻药止痛延时剂 | |
| CN111067919A (zh) | 喷雾止痛剂 | |
| CN103656025B (zh) | 一种跌打药酒 | |
| CA1169774A (en) | Medication having penetration through cutaneous surfaces into articular and muscular areas | |
| JP2007044258A (ja) | 注射針挿入孔付き経皮吸収用パッチ | |
| JP3989188B2 (ja) | 蜂針を用いない蜂毒療法 | |
| US6011061A (en) | Therapeutic methods and preparations using rubidium ions | |
| KR20190117318A (ko) | 우수한 안정성을 갖는 데옥시콜린산 함유 주사제 조성물 및 이의 제조방법 | |
| JPH08500343A (ja) | セシウムイオンを用いた治療方法 | |
| CN100502917C (zh) | 通经活络止痛散 | |
| CN111773262A (zh) | 一种治疗感冒的针灸穴位组合方法及配合使用的穴位贴 | |
| RU2286791C1 (ru) | Способ лечения рубцов | |
| CN1049829C (zh) | 一种用于癌症镇痛的磁药贴 | |
| CN100584375C (zh) | 一种疤痕治疗的新制剂 | |
| CN219835854U (zh) | 一种药贴揿针 | |
| DE10230558B4 (de) | Medizinisches Set zur Verabreichung in einer Kombinationstherapie | |
| RU2200557C1 (ru) | Способ лечения гипертрофических и келоидных рубцов | |
| DE102011117470A1 (de) | Topisch entzündungshemmende Pflaster | |
| US20240065896A1 (en) | Non-Invasive Infused Activated Charcoal Medical Patch | |
| CN108434299B (zh) | 用于治疗肩周炎的药物组合物及其制备方法与喷雾剂 | |
| JPS6229529A (ja) | 病疾患治療薬製造方法 | |
| CN104173658B (zh) | 一种治疗腰肌筋膜炎的外用中药搽剂及其制备方法 | |
| CN1058155C (zh) | 狐臭治疗液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200428 |
|
| RJ01 | Rejection of invention patent application after publication |